Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

Blog - IP Practice
Dec 2025
Identical Inventor Required to Exclude Prior Art
MERCK SERONO S.A. v. HOPEWELL PHARMA VENTURES, INC. Before Hughes, Linn, and Cunningham. Appeal from the Patent Trial and Appeal Board. Summary:  An earlier reference is available as prior art...
Publications
Nov 2025
Jeremiah Helm and Sean Murray’s Discuss Extension of Printed Matter Doctrine in Law360 Column
In their latest Law360 column discussing noteworthy Federal Circuit cases, partners Jeremiah Helm and Sean Murray examine the recent decision in Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals Inc., and how...
Publications
Dec 2025
Knobbe Martens Partners Sean Murray and Jeremiah Helm Examine Federal Circuit Guidance on Patent Wording in Law360
In the latest installment of their monthly Law360 column on recent significant Federal Circuit cases, Knobbe Martens partners Sean Murray and Jeremiah Helm analyze the court’s ruling in Barrette Outdoor...